vs
Pacira BioSciences, Inc.（PCRX）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
BRC Group Holdings, Inc.の直近四半期売上が大きい（$188.3M vs $177.4M、Pacira BioSciences, Inc.の約1.1倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs 1.6%、差は46.3%）。Pacira BioSciences, Inc.の前年同期比売上増加率が高い（5.0% vs -21.9%）。過去8四半期でPacira BioSciences, Inc.の売上複合成長率が高い（-0.2% vs -15.4%）
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
PCRX vs RILY — 直接比較
売上が大きい
RILY
1.1倍大きい
$177.4M
売上成長率が高い
PCRX
+26.9%の差
-21.9%
純利益率が高い
RILY
純利益率が46.3%高い
1.6%
2年売上CAGRが高い
PCRX
2年複合成長率
-15.4%
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $177.4M | $188.3M |
| 純利益 | $2.9M | $90.3M |
| 粗利率 | — | 79.5% |
| 営業利益率 | 3.9% | 32.3% |
| 純利益率 | 1.6% | 47.9% |
| 売上前年比 | 5.0% | -21.9% |
| 純利益前年比 | — | 1710.8% |
| EPS（希薄化後） | $0.07 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上PCRXRILY
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $188.3M | ||
| Q3 25 | $179.5M | $215.3M | ||
| Q2 25 | $181.1M | $188.2M | ||
| Q1 25 | $168.9M | $197.2M | ||
| Q4 24 | $187.3M | $241.0M | ||
| Q3 24 | $168.6M | $225.5M | ||
| Q2 24 | $178.0M | $256.0M |
純利益PCRXRILY
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $90.3M | ||
| Q3 25 | $5.4M | $91.1M | ||
| Q2 25 | $-4.8M | $139.5M | ||
| Q1 25 | $4.8M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-143.5M | $-284.4M | ||
| Q2 24 | $18.9M | $-433.6M |
粗利率PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 79.5% | ||
| Q3 25 | 80.9% | 83.7% | ||
| Q2 25 | 77.4% | 81.3% | ||
| Q1 25 | 79.7% | 81.4% | ||
| Q4 24 | 78.7% | 79.8% | ||
| Q3 24 | 76.9% | 82.1% | ||
| Q2 24 | 75.1% | 84.5% |
営業利益率PCRXRILY
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 32.3% | ||
| Q3 25 | 3.5% | 30.4% | ||
| Q2 25 | 4.7% | 5.7% | ||
| Q1 25 | 1.2% | -31.2% | ||
| Q4 24 | 13.2% | -69.2% | ||
| Q3 24 | -82.8% | -36.4% | ||
| Q2 24 | 15.9% | -90.8% |
純利益率PCRXRILY
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 47.9% | ||
| Q3 25 | 3.0% | 42.3% | ||
| Q2 25 | -2.7% | 74.1% | ||
| Q1 25 | 2.8% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -85.1% | -126.1% | ||
| Q2 24 | 10.6% | -169.4% |
EPS（希薄化後）PCRXRILY
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $2.78 | ||
| Q3 25 | $0.12 | $2.91 | ||
| Q2 25 | $-0.11 | $4.50 | ||
| Q1 25 | $0.10 | $-0.39 | ||
| Q4 24 | $0.38 | $-0.01 | ||
| Q3 24 | $-3.11 | $-9.39 | ||
| Q2 24 | $0.39 | $-14.35 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $144.3M | $226.6M |
| 総負債低いほど良い | — | $1.4B |
| 株主資本純資産 | $653.9M | $-171.5M |
| 総資産 | $1.2B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資PCRXRILY
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $226.6M | ||
| Q3 25 | $246.3M | $184.2M | ||
| Q2 25 | $445.9M | $267.4M | ||
| Q1 25 | $493.6M | $138.3M | ||
| Q4 24 | $484.6M | $146.9M | ||
| Q3 24 | $453.8M | $159.2M | ||
| Q2 24 | $404.2M | $236.9M |
総負債PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $1.4B | ||
| Q3 25 | $376.7M | $1.3B | ||
| Q2 25 | $580.5M | $1.3B | ||
| Q1 25 | $583.4M | $1.4B | ||
| Q4 24 | $585.3M | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
株主資本PCRXRILY
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-171.5M | ||
| Q3 25 | $727.2M | $-260.5M | ||
| Q2 25 | $757.8M | $-351.7M | ||
| Q1 25 | $798.5M | $-496.8M | ||
| Q4 24 | $778.3M | $-488.2M | ||
| Q3 24 | $749.6M | $-497.6M | ||
| Q2 24 | $879.3M | $-218.3M |
総資産PCRXRILY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.6B | $3.2B |
負債/資本比率PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | — | — |
| FCFマージンFCF / 売上 | — | — |
| 設備投資強度設備投資 / 売上 | — | — |
| キャッシュ転換率営業CF / 純利益 | — | 0.29× |
| 直近12ヶ月FCF直近4四半期 | — | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローPCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $26.2M | ||
| Q3 25 | $60.8M | $-60.6M | ||
| Q2 25 | $12.0M | $-25.6M | ||
| Q1 25 | $35.5M | $184.0K | ||
| Q4 24 | $33.1M | $-2.7M | ||
| Q3 24 | $53.9M | $19.5M | ||
| Q2 24 | $53.2M | $111.5M |
フリーキャッシュフローPCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | — | ||
| Q3 25 | $57.0M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $51.6M | — |
FCFマージンPCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | — | ||
| Q3 25 | 31.7% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.0% | — |
設備投資強度PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 0.9% | — |
キャッシュ転換率PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | — | 0.29× | ||
| Q3 25 | 11.20× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
